TORONTO, April 5, 2016
/CNW/ - Mettrum Health Corp. ("Mettrum" or the "Company")
(TSXV:MT), a vertically integrated producer of cannabis products,
is proud to be the exclusive sponsor of a special issue of Current
Oncology that highlights the use of cannabis for cancer patients.
The supplement is aimed at informing the oncological community in
Canada about the role that medical
cannabis and cannabinoids can play in cancer management. The
special issue is guest edited by Dr. Mark
Ware, Director of Clinical Research, Alan Edwards Pain
Management Unit, McGill University
Health Centre, and Executive Director of the non-profit Canadian
Consortium for the Investigation of Cannabinoids (CCIC).
"Finding answers to the questions regarding cannabis and cancer
will require a concerted effort by patients, scientists, clinicians
and the industry," said Dr. Mark
Ware. "We at CCIC are proud to have stimulated this
discussion, and we urge all stakeholders to move forward with the
needed research to address an issue that really is a matter of life
and death."
The treatment of cancer and its symptoms has been recognized as
one of the most critical advances in cannabinoid therapeutics.
"This issue brings together the work of some of the leading minds
around the world who have dedicated themselves and their
laboratories to understanding the role of cannabis and cannabinoids
in the pathophysiology and management of cancer. This
collection of papers takes us on a journey from bedside to bench
and back, and provides a series of important signposts that will
help to chart a path to better cancer care," said Dr. Ware. Print
copies of this supplement will be sent to Current Oncology's 3,200
subscribers. It is also available online, for free, at
www.mettrum.com/oncology.
With new regulatory changes in Canada and the world over, access to a variety
of quality-controlled cannabis-based products and administration
techniques is becoming a reality for patients. "Mettrum is honoured
to be a part of this initiative, helping educate oncologists and
cancer patients about the possible role and benefits of
cannabinoids," said Michael Haines,
CEO of Mettrum. "By arming Canadians – patients, doctors and all
those affected by cancer – with valuable knowledge about the use of
medical cannabis for cancer care, we're hoping to help find
suitable treatments for an illness that is known to impact two out
of every five Canadians."
As a licensed producer of medical marijuana, Mettrum is
dedicated to helping Canadians manage various illnesses and
symptoms with cannabinoid therapies. The partnership with Current
Oncology is one of many steps the company is taking to help educate
the medical community on the benefits and possible clinical uses of
medical cannabis. Other initiatives include the Mettrum
Spectrum™, a trademarked system that helps physicians and their
patients select the cannabis strain or strains that are most
appropriate for their particular medical need, and the recently
launched Mettrum Registry Research Program (MRRP), a Canadian
SHIELD ethics review board approved study that will systematically
gather data on up to 6,000 Canadian patients that have been
prescribed medical cannabis.
About Mettrum Health Corp
Mettrum Health Corp. is a Tier-1 Industry Issuer listed on TSX
Venture Exchange. Mettrum Ltd., a wholly owned subsidiary, is a
Toronto-based company and licensed
producer of medical cannabis under the Marihuana for
Medical Purposes Regulations (Canada) issued pursuant to
the Controlled Drugs and Substances
Act (Canada)
(MMPR). The Company is a leading producer and vendor of medical
cannabis under the MMPR system and has three licensed production
facilities totalling 85,000 square feet representing annual
production capacity of approximately 12,000 kilograms.
About the Mettrum Spectrum™
The Mettrum Spectrum™ is
designed to simplify the dialogue around medical cannabis by
categorizing Mettrum strains according to THC and CBD levels, using
a straightforward, colour-coded system. The adoption of the Mettrum
Spectrum™, allows health care practitioners to recommend strains to
their patients with confidence.
About the Mettrum Registry Research Program
(MRRP)
Mettrum Health Corp. launched the Mettrum Registry
Research Program (MRRP) in early March
2016, to systematically gather data on up to six thousand
Canadian patients who have been prescribed medical cannabis. The
goal of this observational study is to provide information to
prescribing physicians and the wider medical community to help
determine if and how cannabis should be prescribed – focusing on
which strains best suit a particular patient's needs. It also
considers the impact of intercurrent illness or potential
interactions with other medications. The study will run for one
year, with results anticipated to be published by March
2017.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION:
This news release includes certain "forward-looking statements"
under applicable Canadian securities legislation. Forward-looking
statements are necessarily based upon a number of estimates and
assumptions that, while considered reasonable, are subject to known
and unknown risks, uncertainties, and other factors which may cause
the actual results and future events to differ materially from
those expressed or implied by such forward-looking statements. Such
factors include, but are not limited to: general business,
economic, competitive, political and social uncertainties; delay or
failure to receive board, shareholder or regulatory approvals; and
the results of operations. There can be no assurance that such
statements will prove to be accurate, as actual results and future
events could differ materially from those anticipated in such
statements. Accordingly, readers should not place undue reliance on
forward-looking statements. The Company and Mettrum disclaim any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as required by law.
Neither the Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the Exchange) accepts
responsibility for the adequacy or accuracy of this Press
release.
SOURCE Mettrum Health Corp.
